Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 9Endocrine 9Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Thyroid Neoplasms 6Thyroid Cancer, Papillary 3Carcinoma, Medullary 3Adenocarcinoma, Follicular 3Thyroid Diseases 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Melanoma 2Triple Negative Breast Neoplasms 1Thyroid cancer, medullary 1Thyroid cancer, follicular 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Refractory Differentiated Thyroid Gland Carcinoma 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Differentiated Thyroid Cancer (DTC) 1Colorectal Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3FAPI-46 2tislelizumab 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1pembrolizumab 1fludarabine phosphate 1entrectinib 1cabozantinib 1atezolizumab 1alectinib 1Specimen Handling 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Lactones 1Interleukin-2 1Interleukin-13 1Immunotherapy 1Drug Therapy 1Depsipeptides 1Cyclophosphamide 1Cryosurgery 1Biopsy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × cabozantinib × Head & Neck × Clear all
NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡